Scrappy Addex Has A Plan For Reviving Faith In Its Allosteric Modulators
This article was originally published in The Pink Sheet Daily
Executive Summary
With 15 programs in various stages of early development, the Swiss biotech ratchets up the emphasis on partnering to gain back support and non-dilutive capital after the failure of its lead compound.
You may also be interested in...
Third Rock Wise To The Opportunity In CNS; Stakes SAGE Therapeutics With $35 Million
The new company, co-founded by ex-Lilly executive Steven Paul, plans to move aggressively with its allosteric modulators, launching the first of several clinical programs within six months to a year.
Third Rock Wise To The Opportunity In CNS; Stakes SAGE Therapeutics With $35 Million
The new company, co-founded by ex-Lilly executive Steven Paul, plans to move aggressively with its allosteric modulators, launching the first of several clinical programs within six months to a year.
Addex Extends Its Runway With CHF 20 Million Investment By BVF
Last year's failure of GERD candidate ADX10059 enabled BVF to buy in at a value price, but Addex won't make mistake of focusing primarily on one asset again.